Literature DB >> 5129315

Interruption of the enterohepatic circulation of digitoxin by cholestyramine. II. Effect on metabolic disposition of tritium-labeled digitoxin and cardiac systolic intervals in man.

J H Caldwell, C A Bush, N J Greenberger.   

Abstract

Previous studies of digitalis glycoside metabolism and excretion have indicated that these compounds undergo a significant enterohepatic cycle in some species. It has been suggested that the existence of such a cycle in man contributes to the prolonged action of certain cardiac glycosides. Previous studies have demonstrated that cholestyramine binds digitoxin and digoxin in vitro and accelerates the metabolic disposition of digitoxin in rats and guinea pigs, presumably by interrupting the enterohepatic circulation. In order to assess the role of the enterohepatic circulation in the metabolism of digitalis glycosides in humans, maintenance doses of cholestyramine were administered to 7 of 15 normal human subjects beginning 8 hr after digitalization with 1.2 mg of digitoxin-(3)H. All subjects had frequent measurements of serum radioactivity, left ventricular ejection time (LVET), and electromechanical systole (QS(2)), the latter recorded as the interval from onset of Q wave to first major component of second heart sound. Measurement of the LVET and QS(2) intervals affords a sensitive index of the cardiac response to digitalis. In addition, chloroform extraction of serum was performed to separate unchanged digitoxin and active metabolites from cardioinactive metabolites of digitoxin. Cholestyramine treatment resulted in reduction in half-life to total serum radioactivity from 11.5 to 6.6 days, and in chloroform-extractable radioactivity from 6.0 to 4.5 days, as compared to controls. In addition, cholestyramine treatment was accompanied by more rapid return to base line values of digitoxin-induced changes in the LVET and QS(2) intervals. A significant positive correlation was found between QS(2) values and chloroform-extractable radioactivity, the latter reflecting unchanged digitoxin-H(3) (r=0.64; P=<0.01). The results indicate that administration of cholestyramine to digitalized human subjects accelerates the metabolic disposition of digitoxin and abbreviates the physiologic response to the glycoside. This effect is presumably mediated by interruption of the enterohepatic circulation of digitoxin by cholestyramine.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5129315      PMCID: PMC292213          DOI: 10.1172/JCI106764

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  10 in total

1.  Metabolic fate of radioactive digitoxin in human subjects.

Authors:  G T OKITA; P J TALSO; J H CURRY; F D SMITH; E M GEILING
Journal:  J Pharmacol Exp Ther       Date:  1955-12       Impact factor: 4.030

Review 2.  Current techniques for serum or plasma digitalis assay and their potential clinical application.

Authors:  T W Smith; E Haber
Journal:  Am J Med Sci       Date:  1970-05       Impact factor: 2.378

Review 3.  The clinical pharmacology of digitalis glycosides: a review.

Authors:  J E Doherty
Journal:  Am J Med Sci       Date:  1968-06       Impact factor: 2.378

4.  Effect of digitalis on systolic time intervals in heart failure.

Authors:  A M Weissler; C D Schoenfeld
Journal:  Am J Med Sci       Date:  1970-01       Impact factor: 2.378

5.  An improved method of digitoxin therapy.

Authors:  R W Jelliffe; J Buell; R Kalaba; R Sridhar; R Rockwell; J G Wagner
Journal:  Ann Intern Med       Date:  1970-04       Impact factor: 25.391

6.  Intestinal absorption of six tritium-labeled digitalis glycosides in rats and guinea pigs.

Authors:  N J Greenberger; R P MacDermott; J F Martin; S Dutta
Journal:  J Pharmacol Exp Ther       Date:  1969-06       Impact factor: 4.030

7.  Excretion of radioactive digitoxin by the dog.

Authors:  B G Katzung; F H Meyers
Journal:  J Pharmacol Exp Ther       Date:  1965-08       Impact factor: 4.030

8.  Species difference in duration of action of cardiac glycosides.

Authors:  G T Okita
Journal:  Fed Proc       Date:  1967 Jul-Aug

9.  Double isotope dilution derivative assay of digitoxin in plasma, urine, and stool of patients maintained on the drug.

Authors:  D A Lukas; R E Peterson
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

10.  Biotransformation of digitoxin in the dog.

Authors:  B G Katzung; F H Meyers
Journal:  J Pharmacol Exp Ther       Date:  1966-12       Impact factor: 4.030

  10 in total
  15 in total

Review 1.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

2.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 3.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of hypolipidaemic drugs.

Authors:  R Gugler
Journal:  Clin Pharmacokinet       Date:  1978 Nov-Dec       Impact factor: 6.447

Review 5.  Interactions affecting drug absorption.

Authors:  P G Welling
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

6.  Effect of cholestyramine and colestipol on the absorption of phenytoin.

Authors:  J T Callaghan; M Tsuru; J L Holtzman; D B Hunninghake
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  Probable interaction of loperamide and cholestyramine.

Authors:  T Y Ti; H G Giles; E M Sellers
Journal:  Can Med Assoc J       Date:  1978-09-23       Impact factor: 8.262

9.  [Clinical and pharmacokinetic studies in patients with digitalis intoxication (author's transl)].

Authors:  G Bodem; H J Gilfrich; H Aulepp; H Ochs; H J Dengler
Journal:  Klin Wochenschr       Date:  1977-01-01

Review 10.  Adverse effects of hypolipidaemic drugs.

Authors:  L C Knodel; R L Talbert
Journal:  Med Toxicol       Date:  1987 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.